The EU's IP strategy: Enabler or barrier?
EPHA #A2MDialogues
27 October 2020
17:00-18:00
online
Our second dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
How do we ensure that IP incentives compensate and reward innovation but do not distort competition?
What lessons have we learned on IP in the response to COVID19?
Patent-driven innovation may work for profit-driven drug development but it reflects a R&I agenda which favours profit prospects, distortion of competition and market dominance. Additionally, it leads to excessive, unaffordable prices due to monopoly and can stifle meaningful innovation
As the EU prepares to present its IP strategy as well as the scenarios for a review of the legislation on orphan and paediatric medicines, join our experts and key stakeholders who will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition
Panelists
Alfonso Calles-Sanchez
Policy Officer, DG Internal Market, Industry, Entrepreneurship and SMEs (DG Growth)
European Commission
Dimitri Eynikel
EU Policy & Advocacy Advisor
Médecins Sans Frontières Access Campaign
Sergio Napolitano
General Counsel & External Relations Director
Medicines for Europe
Thyra de Jongh
Principal Consultant
Technopolis Group
Moderated by
Yannis Natsis,
Policy Manager, Universal Access to Affordable Medicines
European Public Health Alliance
On Social Media
"We have come a long way in a short time on the issue of #intellectualproperty" @YNatsis kicks off the second of the #A2MDialogues
— EPHA (@EPHA_EU) October 27, 2020
A look back to where the discussion began 4 years agohttps://t.co/IcaEdq1JK6
Thanks to @EPHA_EU for this very interesting session on pharmaceuticals and IP rights. #A2MDialogues
— Tara Hadviger (@hadviger) October 27, 2020
Dimitri makes two very stong points. Patent quality and lack of transparency re R&D cost of drug development. EPO do not always have the mechanism to test if the claims made in application are robust. Perhaps bring leg to force pharma sector to open up re R&D cost #A2MDialogues
— Kanaddy (@DKanaddy) October 27, 2020
Great panel #A2MDialogues today hosted by @YNatsis @EPHA_EU on #intellectualproperty and access to medicines. For more info on SPCs and access to medicines, our article to add to your reading list 👇https://t.co/NU1bFycnrV
— Dimitri Eynikel (@DimitriEynikel) October 27, 2020
Why this hesitation to use the words "compulsory licensing" especially during pandemic times in relation to #A2M access to medicines? Sergio Napolitano finally mentions the Competition Commission. CC need to use exclusionary abuse rules to deal wth excessive pricing #A2MDialogues
— Kanaddy (@DKanaddy) October 27, 2020
— Peter O'Donnell (@podeuropa) October 28, 2020
Find out more about the other #A2MDialogues in the series below
Unleashing meaningful innovation through regulatory reform
19 October 2020
Pharma & COVID19: Winners, losers, prospects
19 November 2020
16:00-17:00 CET
The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
16:00-17:00 CET